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We previously demonstrated that Fibroblast Growth Factor 10 (FGF10) and its receptor FGFR2b play a key role in controlling the very early
stages of mammary gland development during embryogenesis [Mailleux, A.A., Spencer-Dene, B., Dillon, C., Ndiaye, D., Savona-Baron, C., Itoh,
N., Kato, S., Dickson, C., Thiery, J.P., and Bellusci, S. (2002). Role of FGF10/FGFR2b signaling during mammary gland development in the
mouse embryo. Development 129, 53–60. Veltmaat, J. M., Relaix, F., Le, L.T., Kratochwil, K., Sala, F.G., van Veelen, W., Rice, R., Spencer-
Dene, B., Mailleux, A.A., Rice, D.P., Thiery, J.P., and Bellusci, S. (2006). Gli3-mediated somitic Fgf10 expression gradients are required for the
induction and patterning of mammary epithelium along the embryonic axes. Development 133, 2325–35.]. However, the role of FGFR2b
signaling in postnatal mammary gland development is still elusive. We show that FGF10 is expressed at high level throughout the adipose tissue in
the mammary gland of young virgin female mice whereas its main receptor FGFR2 is found mostly in the epithelium. Using a rtTA transactivator/
tetracycline promoter approach allowing inducible and reversible attenuation of the FGFR2b signaling throughout the adult mouse, we are now
reporting that FGFR2b signaling is also critical during postnatal mammary gland development. Ubiquitous attenuation of FGFR2b signaling in the
postnatal mouse for 6 weeks starting immediately after birth is not lethal and leads to minor defects in the animal. Upon dissection of the
mammary glands, a 40% reduction in size compared to the WT control is observed. Further examination shows a rudimentary mammary epithelial
tree with completely absent terminal end buds (TEBs), compared to a well-branched structure observed in wild type. Transplantation of mammary
gland explants into cleared fat pad of wild type mouse recipients indicates that the observed abnormal branching results from defective FGFR2b
signaling in the epithelium. We also demonstrate that this rudimentary tree reforms TEBs and resumes branching upon removal of doxycycline
suggesting that the regenerative capacities of the mammary epithelial progenitor cells were still functional despite long-term inactivation of the
FGFR2b pathway. At the cellular level, upon FGFR2b attenuation, we show an increase in apoptosis associated with a decrease in the proliferation
of the mammary luminal epithelium. We conclude that during puberty, there is a differential requirement for FGFR2b signaling in ductal vs. TEBs
epithelium. FGFR2b signaling is crucial for the survival and proliferation of the mammary luminal epithelial cells, but does not affect the
regenerative potential of the mammary epithelial progenitor cells.
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Mammogenesis in mouse starts approximately on embryonic
day 10.5 (E10.5) with the formation of two mammary lines
running in an antero-posterior direction ventrally between fore
and hind limbs, one line along each flank of the embryo
122 S. Parsa et al. / Developmental Biology 317 (2008) 121–131(Veltmaat et al., 2003, 2004). At around E11.5, lens-shaped
multilayered ectodermal structures (called placodes) can be
detected slightly elevated above the surrounding ectoderm
presumably along each mammary line at five reproducibly
precise positions. These mammary placodes subsequently
transform into bulbs of epithelial cells that are morphologically
distinct from the surrounding epidermis. Approximately on
E15.5, each bud elongates to form a sprout, invading the fat pad
precursor. Each sprout forms a lumen, which opens on the
surface of the skin, where the nipple forms concurrently by
epidermal invagination. At about E16, the first ramifications of
the sprouts occur, and by E18.5 the sprouts have developed into
small, arborized glands. After birth, the gland grows isome-
trically with body growth. The postnatal mammary gland is
mostly composed of ducts that contain two differentiated cell
types, the luminal epithelial cells, which secrete milk protein,
and the myoepithelial cells, which are located at the basal
surface of the luminal cells. Before the start of puberty, the MG
forms a rudimentary network of ductal epithelium. At the onset
of puberty, at around 3 weeks of age, under the action of cir-
culating hormones unique structures called terminal end buds
(TEBs) form at the tips of the mammary ducts (for review see
Veltmaat et al., 2003). These TEBs proliferate, ramify and
actively invade the adipose tissue to allow the formation of a
complex branching structure. This process takes place up to 10–
12 weeks. After this developmental stage, the TEBs regress
(Sternlicht et al., 2006). Little is known about the signaling
pathways controlling in vivo the proliferation of the luminal
cells, which are the cells mostly involved in breast cancer
(Wiseman and Werb, 2002).
We previously reported the crucial role played by Fibroblast
Growth Factor 10/Fibroblast Growth factor Receptor 2b
(FGF10/FGFR2b) in the initial stages leading to the formation
of the mammary placodes. The induction of most of the
mammary line and four of the five mammary placodes on this
line are under the control of FGF10 and FGFR2b (Mailleux et
al., 2002; Veltmaat et al., 2006). We also reported that in Fgfr2b
null embryos, the remaining mammary bud (mammary bud 4)
regressed due to decreased proliferation and increased apoptosis
in the mammary gland epithelium (Mailleux et al., 2002). This
study therefore suggested that the FGFR2b pathway might be
crucial for survival and proliferation of the mammary epithelial
cells during postnatal development.
Indeed, an important role for FGFR2 signaling during
postnatal mammary gland (MG) development is suggested by
the fact that Fgfr2 expression is maximal in mature virgin mice,
declines during pregnancy and lactation, but increases after
weaning (Pedchenko and Imagawa, 2000). The rise in Fgfr2
mRNA in the virgin animal corresponds to a significant increase
in the branching of the mammary epithelial tree. During ductal
development, the genes encoding the two main FGFR2b ligands,
FGF10 and FGF7, are expressed at a ratio of 15 to 1 respectively
(Pedchenko and Imagawa, 2000). The expression ofFgfr2 and its
associated ligands in theMG during ductal development suggests
an important role for the FGFR2b pathway in post-natal growth of
the mammary epithelium. Such a positive role for FGFR2b
signaling in epithelial growth is re-enforced by the fact thatFGF10, which mostly binds to FGFR2b, has been described as an
oncogene in breast cancer cells (Theodorou et al., 2004). In
addition, FGFR2 is amplified and overexpressed in breast cancer
(Grose and Dickson, 2005; Moffa and Ethier, 2007).Mutations in
FGFR2 have recently been strongly associated with a higher risk
of breast cancer in postmenopausal women with no previous
family history of breast cancer (Hunter et al., 2007).
The role of FGF10/FGFR2b signaling in the epithelial/
mesenchymal interactions that characterize postnatal MG
development is demonstrated through the analysis of the MG
phenotype of transgenic mice allowing inducible and reversible
attenuation of the FGFR2b pathway throughout the whole adult
mouse upon addition of doxycycline. This study demonstrates
that FGFR2b signaling in mammogenesis is not only critical
during embryogenesis but also during postnatal development.Materials and methods
Analysis of LacZ expression
Fgf10/LacZ expression was monitored in Fgf10LacZmice (Kelly et al., 2001)
by β-galactosidase activity using whole-mount and histological revelation as
described by Kelly et al. (1995). Mammary glands (MGs) from 3-week-old
virgin females were fixed 2 h in 4% PFA. Following the fixation, the MGs were
washed in 1× PBS and stained in X-gal solution. A similar protocol was carried
out for MG from Rosa26 mice (Zambrowicz et al., 1997).
Generation of rtTA; tet(O)sFgfr2b animals
CMV-Cre mice (Schwenk et al., 1995) were crossed with rtTAflox mice
(Belteki et al., 2005) to generate rtTA mice expressing rtTA from the Rosa26
promoter in every single cell of the body. rtTA mice are now crossed with tet(O)
soluble Fgfr2bmice (Hokuto et al., 2003) to generate double transgenic rtTA; tet
(O)soluble Fgfr2b mice. These mice are on the CD1 mixed genetic background
and allow inducible and reversible attenuation of the FGFR2b pathway in the
embryo or mouse simply by feeding the mice with doxycycline containing food
(Rodent diet with 0.0625% Doxycycline, Harlan Teklad TD01306). The
reversibility of the phenotype is studied by putting the treated mice on normal
food. Genotyping of each allele was done as previously described (Schwenk et
al., 1995; Belteki et al., 2005; Hokuto et al., 2003).
Antibodies
MG from 3-week-old female mice were fixed in 4% PFA overnight and
stored in 70% ethanol. The tissues were embedded in paraffin and 5 μm
longitudinal sections were made. IHC was performed with the Envision kit from
Dako cytomation. FGFR1 antibody (Flg, 1:200, Santa Cruz Inc.) and FGFR2
(Bek, 1:200, Santa Cruz, Inc) were incubated overnight at 4 °C as previously
described (Sala et al., 2006). MG paraffin sections were treated with Cy3
conjugated-monoclonal anti α-SMA Ab (1:200, Sigma, clone 1A4) as
previously described (De Langhe et al., 2005). Photomicrographs were taken
using a Leica DMRA fluorescence microscope with a Hamamatsu Digital CCD
Camera.
Proliferation
One of the two MGs number 4 from P35 WT and double transgenic animals
(n=3 for each) non-induced with dox (control group) were surgically removed
and the operated mice were put on doxycycline food for 1 week to induce gene
expression. Similar experiments were also carried out with P60 double
transgenic animals (n=3) to assess the role of FGFR2b signaling in late
puberty. After a week, the animals were sacrificed and the second mammary
glands 4 were removed (experimental group). The mammary glands were fixed
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70% EtOH overnight and stored in 100% EtOH. The samples were then
embedded in paraffin and sections (5 μm) were cut. The PCNA staining kit
(Zymed Labs Inc. 93-1143) was used for immunostaining. The total number of
cells in the epithelium as well as the number of PCNA positive cells in the
epithelium were scored in six photomicrographs (64× magnification), in random
portions of a section of three independent mammary glands in the experimental
and control group. A total number of 600 cells were counted per sample. The
significance in proliferation in mammary glands between control and
experimental group was evaluated by one-tailed paired t-test. P values less
than 0.05 were considered to be statistically significant. To assess the effect of
inactivating FGFR2b signaling on the overall ramification process, mammary
glands from the control and experimental group were also stained with Carmin
Red.
Analysis of cell death
Apoptotic cells on 5 μm paraffin section of P35 and P38 (days on dox) MG
were detected by the incorporation of terminal deoxynucleotidyltransferase
mediated dUTP nick-end labeling (TUNEL) using the “In Situ Cell Death
Detection, Fluorescein” kit (Roche Applied Science) as recommended by the
manufacturer. The total number of cells in the epithelium as well as the number
of TUNEL positive cells in the epithelium were scored in five photomicrographs
(64× magnification), in random portions of a section of three independent
mammary glands in the experimental and control group. A total number of 500
cells were counted per sample.
Whole mount Carmin Red staining
The mammary gland epitheliumwas stained using Carmin Red as previously
described (Faraldo et al., 1998).
Quantification of the mammary gland size
Mammary glands fromWTand mutant animals (treated with dox from P0 to
P42, n=3) were spread out flat on a glass slide and photographed at the same
magnification (0.6×). The surface occupied by the MG (in arbitrary units) in the
total field was measured using Metamorph. The significance in the size of the
mammary glands between WT and mutant was evaluated by one-tailed paired
t-test. P values less than 0.05 were considered to be statistically significant.Fig. 1. Expression of FGFR1, FGFR2 and FGF10 in WT mammary gland. Expressio
(C) Expression of FGFR2 is also detected in the terminal end bud epithelium in 5
animals. (E and F) Paraffin section of panel D. Low and high magnification. Note th
adip.: adipocytes; p.f.: periductal fibroblast. Scale bar: (A, B, C, F) 120 μm; (D) 20Grafting of wild type and mutant mammary gland in cleared
mammary fat pad of NOD/SCI mice
The mammary gland 4 from WT (n=2) and Mutant (n=2) at P21 were
freshly dissected and individually cut in 1 mm3 explants (8–10 pieces/MG).
Explants were then transplanted into cleared mammary fat pads of NOD/SCID
mice (Medina, 1996). In these experiments, 19-day-old females were used as
transplant recipients. The endogenous mammary epithelium was surgically
removed from the fourth inguinal glands to provide a cleared mammary fat pad.
Mutant and wild-type mammary gland explants were transplanted separately
into contralateral glands of each recipient to ensure an identical host
environment. 1 week after surgery, the animals were put either on doxycycline
food (n=10 animals) or normal food (n=8 animals). The mice were sacrificed
9 weeks after surgery and the fourth inguinal mammary glands dissected. The
epithelium was stained using Carmin Red as previously described (Faraldo et al.,
1998). The number of cleared fat pad filled with mammary gland epithelium was
quantified.Results
Expression of FGF10 and associated receptors FGFR1 and
FGFR2 in the mammary gland of young virgin females
Immunohistochemistry in mammary glands of 3-week-old
virgin females was carried out to determine the expression of
FGFR1 and FGFR2. The antibodies used recognize both the “b”
isoform, usually expressed in epithelia and the “c” isoform
generally expressed in mesenchyme. FGF10 binds to the “b”
isoform of both receptors. Fig. 1A shows that FGFR1 is detected
at high level in the adipose tissue and at very low level in the
epithelium. By contrast, FGFR2 is strongly detected in the ductal
epithelium and expressed at lower levels in the adipose tissue.
FGFR2 is also expressed in the epithelium of the terminal end
buds located at the tips of the ducts in 5-week-old MG (Fig. 1C).
The expression of Fgf10 in mammary glands of 3-week-old
virgin females was also determined using Fgf10LacZ micen of FGFR1 (A) and FGFR2 (B) in 3-week-old MG by Immunohistochemistry.
-week-old female mice. (D) X-gal staining of 3-week-old MG from Fgf10LacZ
e blue dots in the adipocytes corresponding to nuclear β-galactosidase staining.
0 μm, (E) 700 μm, (F) 200 μm.
Fig. 2. Validation of the double transgenic (rtTA; tet(O)soluble Fgfr2b)
embryonic and adult mice. (A, B) Pregnant females carrying single or double
transgenic embryos have been fed with doxycycline-containing food since
embryonic day 0.5. Embryos at embryonic day 13.5 from doxycycline treated
pregnant females were collected and genotyped to confirm the presence of both
rtTA and tet(O)sFgfr2b transgene. Single transgenic and wild type embryos had
the same phenotype. (A) Single transgenic/WT embryo. (a) H&E staining of a
frontal section going through the lung. Note the presence of a well-developed
lung. (B) By contrast double transgenic embryos exposed to doxycycline had no
limbs (arrows) and a curly tail (arrowhead). (b) H&E staining of a frontal section
going through the lung. Note the abnormal lung comprised only of the trachea
and the first two bronchi. (C) Double transgenic adult female mice were fed with
normal food or doxycycline-containing food from birth (P0). 2-month-old
female mice are shown in panel C. Note that the treated mouse appears slimmer.
(D) Weight quantification in 2-month-old wild type and mutant mice show
reduction in weight in both males (n=2 for each genotype) and females (n=2 for
each genotype) mutant mice. (E–H) Obvious macroscopic defects in 3-month-
old doxycycline-treated female mice included the absence of upper incisors and
the degraded lower incisors (compare insets in panels E and F) as well as the
longer nails (compare panels G and H).
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galactosidase expression in this mouse strain is a bona fide
reporter for Fgf10 expression (Kelly et al., 2001; Mailleux et
al., 2005; Sala et al., 2006; Veltmaat et al., 2006). We found that
Fgf10/β-galactosidase is expressed at high level in the
adipocytes but not in the epithelium (Figs. 1D–F) confirming
our previous studies showing embryonic Fgf10 expression in
the fat pad (Mailleux et al., 2002), an embryonic tissue which
gives rise to the white adipose tissue.
These data therefore suggest that FGF10 produced in large
amount by the adipocytes acts in a paracrine fashion on the
epithelium expressing FGFR2.
Attenuation of FGFR2b during embryonic and postnatal stages
demonstrate a differential requirement for FGFR2b signaling
To determine the role of FGFR2b signaling during postnatal
stages, transgenic mice were generated to allow doxycyclin-
based inducible and reversible attenuation of FGFR2b signal-
ing. CMV-Cre mice, a Cre-transgenic mouse strain allowing
ubiquitous deletion of loxP-flanked gene segments including
deletion in germ cells (Schwenk et al., 1995) were crossed with
rtTAflox mice (Belteki et al., 2005). After recombination of the
rtTAflox allele, the transactivator rtTA is constitutively expressed
from the Rosa 26 locus in every cell of the mouse including the
germ cells. This constitutive rtTA mouse line was then crossed
with tet(O)sFgfr2b responder line (Hokuto et al., 2003) to
generate double transgenic animals allowing ubiquitous expres-
sion of soluble FGFR2b, acting as a dominant negative, from
every cell of the mouse using the rtTA transactivator/
tetracycline promoter system (Gossen and Bujard, 1992). We
have validated that our double transgenic system is functional
by inducing the expression of soluble FGFR2b from embryonic
day 0.5 (E0.5) through E13.5. Our results indicate that double
transgenic embryos exposed to doxycycline exhibit the
phenotype of the previously reported Fgfr2b−/− embryos (De
Moerlooze et al., 2000). rtTA; tet(O)sFgfr2b double transgenic
embryos not exposed to doxycycline as well as single transgenic
embryos exposed to doxycycline were phenotypically identical
to wild type embryos (data not shown). This demonstrates that
there is no leakiness in the expression of soluble FGFR2b in our
double transgenic embryos in absence of doxyclycline and that
there is no toxic effect of doxycycline on embryonic
development.
A comparison of Fig. 2A (showing a single transgenic em-
bryo identical to wild type) with Fig. 2B indicates that double
transgenic embryos exposed to doxycycline fail to form limbs
and lungs (compare insets a and b). In addition, we observed a
curly tail, which is a phenotype observed in Fgfr2b−/− embryos
(de Moerlooze et al., 2000) but not in Fgf10−/− embryos
(Sekine et al., 1999). These results confirm that FGFR2b
signaling is crucial during organogenesis. By contrast, expres-
sion of a dominant negative FGFR2b during the postnatal
period (P0 through P60) leads only to a few defects such as
abnormally shaped incisors and elongated claws (Figs. 2E–H).
As during embryonic stages, adult double transgenic mice not
exposed to doxycycline are phenotypically equivalent to wildtype mice (data not shown) indicating that there is no leakiness
in the expression of soluble FGFR2b in post-natal stages. The
mutant mice also appear significantly slimmer compared to wild
type animals (Fig. 2C). Quantification of the weight shows
indeed a significant reduction in mutant (n=4) vs. wild type
125S. Parsa et al. / Developmental Biology 317 (2008) 121–131(n=4) animals regardless of the gender (Fig. 2D, Pb0.03).
Upon dissection of the mammary glands (MG) from control
(wild type) and double transgenic animals, we observed a 40%
reduction in the total size (measured in arbitrary units) of the
mutant MGs (7451±881 vs. 12477±1123 in mutant vs. control,
Pb0.02) as well as reduced visceral fat (data not shown). Our
double transgenic system relies on the proper activity of the
Rosa26 promoter in different tissues allowing expression of
the transactivator rtTA. As a control for these experiments, the
activity of the Rosa26 promoter was determined by examining
β-galactosidase activity in skin, limbs, gastrointestinal tract,
heart, kidneys, lungs and MGs of adult Rosa26 mice. In all
organs examined (data not shown), including the MGs (Figs.
3A–C), a robust and homogenous expression of β-galactosi-
dase was observed. The use of the Rosa26 promoter to drive
significant gene expression in major organs in adult mice was,
therefore, validated.
Altogether, the data suggest that FGFR2b signaling is not
essential for the function/homeostasis of organs important forFig. 3. FGFR2b attenuation prevents the formation of the mammary epithelial tre
galactosidase activity throughout the mammary epithelium and weak expression leve
mutant MG exposed to dox from P0 through P42. (D) WT MG at P42 showing exten
the TEBs. (F) Higher magnification of the TEBs shown in panel E. Insets show H&E
myoepithelial cells. (G) MG from rtTA; tet(O)sFgfr2b females exposed to doxycyclin
in panel G. Note the absence of TEBs at the extremity of the ducts. (I) Higher magnifi
duct with a simplified epithelium. SMA is expressed normally in the mutant MG. Sca
and I, 300 μm.sustaining the vital functions of the mice such as the lung, heart,
digestive tract or kidneys. However, discrete defects unravel a
function postnatally for FGFR2b in specific organs such as the
incisors, the claws or the MGs. In this study, potential MG
defects in rtTA; tet(O)sFgfr2b double transgenic animals were
examined. To obtain consistent results, the analysis focused on
MG 4 even though similar results were obtained with the other
pairs of MGs (data not shown). Easy accessibility and dissection
dictated the choice of this mammary gland.
Attenuation of FGFR2b signaling immediately after birth leads
to absence of branching of the mammary epithelium
LacZ expression in 8-week-old MG from Rosa26 mice
shows that the Rosa26 promoter is active throughout the
mammary epithelium both in proximal (ductal) and distal (tip)
position. LacZ expression was also detected throughout the
white adipose tissue, but at lower level. The expression of
soluble Fgfr2b indirectly from the Rosa26 promoter is thereforee. (A–C) Rosa26 MG from P120 female stained with X-gal shows strong β-
ls in the white adipose tissue. (D–I) Carmin Red staining of P42 MG in WT and
sive branching of the epithelial tree. (E) High magnification of panel D showing
staining of the ductal epithelium as well as SMA expression by IF to label the
e for 42 days since birth. (H) Higher magnification of the rudimentary tree shown
cation of the ducts shown in panel H. Insets show H&E staining of the mammary
le bar: (A, D, G) 1000 μm; (B, E, H) 400 μm; (C, F, I) 80 μm. Insets in panels F
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Carmin Red staining of wild type and double transgenic
animals exposed to doxycycline postnatally for various period
of time was carried out. Fig. 3 shows the degree of ramification
in wild type (Figs. 3D–F) and rtTA; tet(O)sFgfr2b (Figs. 3G–I)
mammary glands after 42 days of treatment with doxycycline
(from P0 to P42). In the wild type MG (n=3) a well-developed
mammary tree extending beyond the lymph node used as a
landmark is observed with prominent terminal end buds
(TEBs). By contrast, the epithelial tree of the mutant MG
(n=5) did not reach the first lymph node but rather stayed close
to the nipple region. Further examination indicated a poorly
branched structure with rudimentary, thin ducts and no visible
TEBs. Histological analysis revealed a simplified luminal
epithelium (compare insets in Figs. 3I and F). Normal SMA
expression in mutant MG indicates that the myoepithelial layer
is not significantly affected (inset in Fig. 3I).
The role of FGFR2b signaling in the mammary gland
during gestation and lactation was also examined. Pregnant
double transgenic (n=2) and WT (n=4) females (which were
crossed with wild type males) were compared. Doxycycline
treatment of pregnant double transgenic mice (from E7
through E14) led to a slight reduction in the formation of
the alveoli compared to the WT MG (Supplementary Fig. S2,
A–F). However, when double transgenic mice are treated
during the early lactation period (from P0 through P7), no
major defects can be detected compared to WT MG (Fig. S2,
G–L). Supporting the conclusion that lactation is not affected,
the difference in the weight of the P7 pups in the WT and
double transgenic group was not significant (6.1 g±0.2 g vs.
6.3 g±0.4 g, for pups in WT females vs. double transgenic,
P=0.14).
Thus our results indicate that FGFR2b signaling is crucial for
mammary epithelial branching during early-mid puberty. It also
suggests that ductal epithelium, even though affected, is less
dependent on the loss of FGFR2b signaling than the epithelium
in terminal end buds.
The rudimentary mammary tree resumes branching upon
removal of doxycycline
Upon removal of doxycycline the rtTA/Tet(on) system
allows reversibility in the expression of the gene under the
control of the tetracycline promoter (Gossen and Bujard, 1992).
The study takes advantage of this feature to further evaluate the
regenerative capacities of the epithelial progenitor cells in
mutant mammary glands of female mice exposed to doxycy-
cline for 42 days (from P14 to P56). In this experiment we have
chosen to induce expression of doxycycline at P14 instead of P0
as we also wanted to determine also the effect of expressing
soluble FGFR2b on the mammary epithelium: namely, growth
arrest vs. regression of the mammary epithelial tree. As mouse
mammary glands come in pairs, one of the two MG of a given
pair can be ressected for evaluation without sacrificing the
animal. At a later time, the second MG can be isolated and
compared to the first MG from the same animal, therefore
reducing sample-to-sample variability.Fig. 4 summarizes the experimental plan. In wild type mice
(n=3), the first MG at P14 and the second MG at P84 were
isolated. In double transgenic mice (n=3), treatment was
started with doxycycline at P14 and the first MG was isolated
at P56. MGs from P56 WT animals were also isolated
independently as age-matched controls. P14 WT MGs were
isolated, as this is the stage when the mutant mice were put on
doxycycline. This allows determining whether the develop-
ment of the rudimentary tree is simply arrested immediately at
the time of doxycycline treatment or if further regression
occurs. We therefore compared mutant P56 MG (Figs. 4D–F)
with wild type P14 and P56 MG (Figs. 4A–C and G–I,
respectively). The results indicate that, in spite of a well-
developed white adipose tissue, the mutant mammary gland
(at P56) exhibits a significant decrease in lateral ramifications
compared to the control wild type MGs at P14 and P56.
Interestingly, the main ducts are still maintained in the mutant
MG suggesting again a differential requirement for FGFR2b
signaling in the ductal vs. terminal end bud epithelium. This
result suggests that attenuation of FGFR2b signaling in
already formed post-natal mammary gland not only arrests
the growth of the epithelial tree but also leads to its partial
regression.
To determine whether the regenerative capacities of the
mammary epithelial progenitors were still functional in the
rudimentary epithelial tree observed in the mutant MG, the
operated mutant animals (P56) were put on normal food (with
no doxycycline) for 28 days (until P84). At the end of this
period (P84) the second MG4 was surgically removed from
wild type and mutant animals. Figs. 4M–O show that upon
doxycycline removal the mutant MG epithelium can indeed
reform TEBs and resume branching beyond the lymph node.
However, close comparison with the corresponding wild type
MG (Figs. 4J–L) indicates that the P84 mutant MG resembles a
MG from a younger animal, such as the one presented in Fig.
3D (P42 WT virgin female). This result therefore indicates the
FGFR2b pathway in postnatal MG is not critical for the
maintenance of the regenerative capacity of the epithelial MG
progenitors cells.
Attenuation of FGFR2b signaling leads to a drastic decrease in
the proliferation of the mammary luminal epithelium
FGFR2 expression in the mammary epithelium (Fig. 1) as
well as the resulting rudimentary epithelial mammary tree
upon FGFR2b attenuation (Figs. 3 and 4) suggest that FGF10
acts on the epithelium to control its survival and proliferation.
To determine that this is indeed the case, one of the two MG4
in P35, mid–puberty, wild type and mutant females (n=3)
which were never fed with doxycycline was surgically
removed and the operated animals were fed with doxycycline
food for 1 week. The second MG4 (at P42) was then sur-
gically removed. Therefore control and experimental mam-
mary glands were obtained from the same animals, reducing
the variability due to the mixed genetic background.
Comparison of P35 (no dox, Figs. 5A–C) vs. P42 (1 week
on dox, Figs. 5D–E) wild type MG indicates no changes in
Fig. 4. FGFR2b pathway in postnatal MG is not critical for the maintenance of the regenerative capacities of the epithelial MG progenitor cells. Analysis of MG
development by Carmin Red staining. (A–C) P14 Wt MG showing that the mammary tree does not reach the lymph node (L). (D–F) MG from rtTA; tet(O)sFgfr2b
female mouse treated with dox from P14 through P56 showing that the growth of the mammary tree is arrested. In comparison, the white adipose tissue is not
significantly affected. Note the marked reduction in lateral branches and the absence of TEBs. (G–I) Corresponding P56 age matches WT control MG. (J–L) P84 Wt
MG showing that the mammary tree grows beyond the lymph node. Note also the abundant lateral ramifications in the mammary tree. (M–O) MG from a rtTA; tet(O)
sFgfr2b female mouse treated with doxycycline from P14 through P56 and then fed with normal food up to P84. Note that the TEBs are present and that the growth of
the mammary tree has resumed. Scale bar: (A, D, G, J, M) 1000 μm; (B, E, H, K, N) 400 μm; (C, F, I, L, O) 80 μm.
127S. Parsa et al. / Developmental Biology 317 (2008) 121–131the appearance of the mammary epithelial tree indicating that
doxycycline treatment per se does not affect MG develop-
ment. In addition, mutant MG at P35 shows well-developed
TEBs, a feature of WT MG, therefore supporting our previousconclusion that there is no leakage of soluble Fgfr2b ex-
pression in absence of doxycycline. By contrast, mutant MG
at P42 (1 week on dox) displays a specific regression of the
TEBs (Figs. 5J–L).
Fig. 5. FGFR2b signaling attenuation leads to decreased proliferation of the mammary epithelium. Analysis of the MG phenotype isolated from the WTor rtTA; tet(O)
sFgfr2b female non-treated with dox (P35) and then treated with dox for 1 week (P42). Analysis was done by Carmin Red staining. (A–C) Low and high magnification
of P35 MG from WT female non-treated with doxycyline showing a normally ramified mammary tree. (D–F) P42 WT female treated with doxycyline for 1 week
showing a normally ramified mammary tree. (G–H) Low and high magnification of P35 MG from rtTA; tet(O)sFgfr2b female non-treated with doxycyline showing a
normally ramified mammary tree. (J–L) P42 MG from rtTA; tet(O)sFgfr2b female treated for 1 week (from P35) with doxycyline showing the main ducts with no
visible TEBs. (M–P) Corresponding PCNA staining indicating decrease proliferation in the luminal epithelium in mutant MG exposed to dox (P) vs. mutant MG not
exposed to dox (O) or wild type controls (M,N). Scale bars: (A, D, G, J) 1000 μm; (B, E, H, K) 400 μm; (C, F, I, L) 80 μm; (M, N) 60 μm; (O, P) 120 μm.
128 S. Parsa et al. / Developmental Biology 317 (2008) 121–131Our results also indicate similar expression of SMA in P35
MG compared to P42 MG (data not shown), suggesting that the
myoepithelial layer is not directly affected by FGFR2b
attenuation. The proliferation in the luminal epithelium of
mutant MG with or without doxycycline by PCNA was then
examined. A 65% decrease in proliferation in P42 (Fig. 5N) vs.
P35 MG (Fig. 5M) (16.1±3.8% vs. 48.4±2.1% for P42 vs. P35,
respectively. Pb0.001) was observed. Similar results were
obtained in late puberty (P60–P67, Fig. S1). An 83% decrease
in proliferation in P67 (7 days on dox) vs. P60 (no dox) mutant
MG (Fig. S1) (5.9%±1.6% vs. 34.0%±6.2% for P67 vs. P60,
respectively. Pb0.001) was recorded.
Our results indicated no difference in apoptosis after 1 week
treatment with doxycycline either at mid or late puberty (datanot shown). However, significant apoptosis was detected in
mutant MG after 3 days treatment (between P35 and P38) with
doxycycline (Figs. 5O,P; 8.6±2.8% vs. 2.4±0.6% at P38 vs.
P35, Pb0.01). Altogether our results demonstrate that FGFR2b
signaling controls luminal epithelial cell proliferation as well as
survival.
Branching of mutant mammary explants is severely impaired in
cleared mammary fat pad of recipient mice exposed to
doxycycline
To confirm that the observed defects in the mutant mammary
glands were directly linked to the perturbation of the FGFR2b
signaling in this organ and not the result of systemic changes in
129S. Parsa et al. / Developmental Biology 317 (2008) 121–131hormones, transplantation of explants from wild type and
mutant 3-week-old MG into 19-day-old cleared fat pads of
NOD/SCID female mice was performed. Half of the recipient
mice containing the mutant or wild type explants were fed with
doxycycline containing food 1 week after surgery. The animals
were sacrificed 9 weeks after transplantation and the develop-
ment of the explants was examined. The fate of the explants into
the fat pads was divided into three possible outcomes; ramified
explants, explants present with no ramification and no explant
visible. In the later case, the lack of visible explants in the fat
pad is likely the consequence of failure to implant due to
technical reasons.
For WT explants (no doxycycline, Figs. 6A,B), a total of 8
transplanted fat pad (TFP) were considered. 87.5% of TFP show
ramified explants, 0% of the TFP show explants with no
ramification and 12.5% of the TFP show no explants indicating
failure of the explants to engraft. Similar results were observed
for WT explants exposed to doxycycline (Figs. 6C,D). For the
mutant explants without doxycycline (Figs. 6E,F), a total of 8
TFP were considered. 75% of the TFP show ramified explants,
12.5% of the TFP show explants with no ramification and
12.5% of the TFP show no explants. This once again
demonstrates that there is no leakage of soluble Fgfr2b
expression in the double transgenic system. Finally, for the
mutant explants on doxycycline, a total of 10 TFP were
considered. 20% of the TFP show ramified explants, 60% of the
TFP show explants with no ramification such as the one shown
in Figs. 6G,H and 20% of the TFP show no explants. Altogether
our results indicate a drastic decrease in the TFP with mutant
explants showing ramification in doxycycline vs. normal food
(20% vs. 75%, respectively). This outcome indicates that the
effect of FGFR2b signaling on the mammary epithelium is not
the consequence of alterations in the white adipose tissue and/or
in levels of hormones known to control mammary branching
morphogenesis such as estrogen, progesterone and prolactin.Fig. 6. Evidence that FGFR2b signaling in post-natal mammary gland development
transplanted in cleared fat pad of recipient animals. Animals were fed with dox or nor
stained with Carmin Red. (A,B) Recipient mouse is not exposed to doxycycline. F
Recipient mouse is exposed to doxycycline. No difference with panels A,B. (E,F) Re
shows presence of epithelial ramification. (G,H) Recipient mouse is exposed to dox
1000 mm; (B, D, F, H) 400 μm.Discussion
An inducible and reversible expression system to attenuate
FGFR2b signaling in the postnatal stages
We are the first group to report the use of the rtTA/Tet(on)
system to attenuate ubiquitously FGFR2b signaling in postnatal
mice. In contrast to the severe phenotype observed when
FGFR2b is knocked down during the embryonic stage, we
could detect only minor defects when FGFR2b is inactivated in
the postnatal period. These defects include defective incisors,
longer claws and reduced white adipose tissue. Interestingly, the
incisors unlike the molars are constantly renewed in the
postnatal mouse. Indeed, it was previously suggested by Harada
and colleagues that FGF10 maintains the dental epithelial stem
cell compartment in the incisors, not only during the embryonic
stages, but also postnatally (Harada et al., 2002; Yokohama-
Tamaki et al., 2006). Our study directly confirms the important
role for FGFR2b signaling during postnatal incisor develop-
ment. The longer claw phenotype observed upon attenuation of
the FGFR2b pathway is more surprising as usually loss of
FGFR2b signaling leads to loss of tissue. However, this
phenotype is similar to the one displayed by mice where
soluble FGFR2b is expressed in the hair cortex using the Foxn1
promoter (Schlake, 2005). More work will be needed to
determine the mechanisms leading to the claw phenotype.
Finally, the mice under long-term treatment with doxycycline
exhibit a significant decrease in the white adipose tissue,
illustrated by the reduced size of the mammary gland and
visceral fat in mutant animals (data not shown). Such decrease is
not observed when mice are treated for a week (data not shown).
Even though we cannot exclude that this reduced weight is the
consequence of malnutrition due to defective incisors, it is
likely that in our system, FGFR2b attenuation is also disrupting
the formation of the white adipose tissue as previously reportedis epithelial cell autonomous. MG explants from WT and mutant animals were
mal food 1 week after surgery and sacrificed 9 weeks after surgery. Fat pads were
at pad from with WT explant shows presence of epithelial ramification. (C,D)
cipient mouse is not exposed to doxycycline. Fat pad from with mutant explant
ycycline. Fat pad with mutant explant does not ramify. Scale bar: (A, C, E, G)
130 S. Parsa et al. / Developmental Biology 317 (2008) 121–131(Yamasaki et al., 1999). It has been proposed that FGF10
controls adipogenesis by inducing the differentiation of the
progenitors for the adipocytes (called pre-adipocytes) into
adipocytes (Sakaue et al., 2002). More recently, it has been
shown that FGF10 plays also a key role in the proliferation of
the pre-adipocytes (Asaki et al., 2004). Collectively, these
results indicate that long-term attenuation of FGFR2b signaling
in postnatal mice leads to defects consistent with an important
role of FGFR2b in survival and/or proliferation of progenitor
and/or partially differentiated cells in the incisors and adipose
tissue.
FGFR2b signaling plays a major role during postnatal
mammary gland development
The mammary gland is mostly composed of ducts that
contain two differentiated cell types, the luminal epithelial cells
and the myoepithelial cells. Before the start of puberty, the MG
forms a rudimentary network of ductal epithelium. At the onset
of puberty, under the action of circulating hormones, terminal
end buds (TEBs) form at the tips of the mammary ducts. These
TEBs proliferate, ramify and actively invade the adipose tissue
to allow the formation of a complex branching structure. Using
an inducible and reversible FGFR2b attenuation approach, this
study demonstrates a differential requirement for FGFR2b sig-
naling in the ductal vs. terminal end bud epithelium. In par-
ticular, we show that the proliferation of the luminal epithelium
is dependent upon FGFR2b signaling. Such a positive role for
FGFR2b signaling in mammary epithelial growth is reinforced
by the fact that FGF10 has been described as an oncogene in
breast cancer cells (Theodorou et al., 2004).
Could estrogen activity on the mammary gland epithelium be
mediated by FGFR2b signaling?
During puberty, the mammary epithelial tree develops
rapidly in response to changes in circulating hormones,
including estrogen. The role of estrogen receptor α (Erα) in
mammary gland development was previously reported by
Kourach and colleagues in their genomic Erα KO mouse model
(Bocchinfuso et al., 2000; Korach et al., 1996). These mice,
which turned out to be hypomorphic for Erα, displayed lack of
MG development beyond the pre-pubertal stage with absence of
TEBs and a rudimentary epithelial tree. However, later studies
demonstrated that this phenotype could be rescued by prolactin,
estradiol or progesterone demonstrating that the phenotype was
due to abnormal pituitary and ovarian hormones in the mutant
animals whereas Erα function was intact in the mammary gland.
To address the function of estrogen signaling in the mammary
epithelium, recent studies described the mammary epithelial
specific inactivation of Erα (Feng et al., 2007). The resulting
mutant mammary gland displayed an arrest in MG development
beyond the pre-pubertal stage with absence of TEBs. Given the
phenotypic similarities between our mutant MG and the Erα
MG described previously, it is obvious to speculate that
estrogen signaling via Erα in the epithelium could regulate
the expression of FGFR2b in this compartment. Interestingly,FGFR2 expression in the prostate epithelium, which is also
under hormonal control for its postnatal development, appears
to be required for androgen-mediated tissue homeostasis (Lin et
al., 2007). Therefore by keeping the level of FGFR2b
expression under control, estrogen signaling would prevent
mammary epithelial cells to respond excessively to the
otherwise high levels of FGF10 arising from the surrounding
stroma. Further studies using the available mutant mice and in
vitro cell modeling will allow determining the possible
relationship between FGFR2b signaling acting locally during
mammary gland morphogenesis and the circulating hormones.
In conclusion, we report herein that FGFR2b signaling in
mammogenesis is not only critical during embryogenesis to
control the induction of the mammary placodes (for placodes 1,
2, 3 and 5), as well as to maintain the survival and proliferation
of the mammary epithelial progenitor cells in placode 4
(Mailleux et al., 2002) but also during postnatal development
to allow the formation and maintenance of the TEBs as well as
the control of survival and proliferation of the luminal epithelial
progenitor cells.
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